AdAlta and GPCR Therapeutics collaborate on novel cancer therapeutics
MELBOURNE Australia and SEOUL South Korea, 13 October 2022: AdAlta and GPCR Therapeutics form collaboration to evaluate a new cancer treatment approach combining beta blockers plus AdAlta’s CXCR4-inhibiting i-bodies. CXCR4 is overexpressed in more than 23 cancers and drugs targeting the CXCR4 pathway address a multi-billion dollar opportunity. AdAlta has the first option to license and further commercialise any products resulting from the collaboration.
